Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Activated CIK and anti-CD3-MUC1 bispecific antibody in advanced pancreatic cancer
NCT03509298Phase 2Withdrawn
- Sponsor
- Fuda Cancer Hospital
- Start
- Apr 2018
- Primary completion
- May 2020
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Activated CIK + CD3-MUC1 bispecific antibody in pancreatic cancer (PC), sponsored by Fuda Cancer Hospital. Primary endpoint: Objective Response Rate at 1 year. Planned start Apr 2018; status: withdrawn.
02
Drugs
Activated CIK + CD3-MUC1 bispecific antibody
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03509298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03509298.